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Results
Methods
■ Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder, characterised by insulin (INS) insensitivity
as a result of INS resistance and beta-cell dysfunction, with a globally steady increase in prevalence. In 2011 alone, approximately 2.9 million new cases of T2DM were diagnosed within the UK 1 . ■ The cost of T2DM accounts for 7-12 % of the total UK National Health Service (NHS) expenditure 2 , and thus, the choice of a cost-effective treatment is important. ■ Following NICE guidelines, oral dual therapy consisting of metformin (MET) and sulfonylureas (SU) is recommended when monotherapy is not well tolerated or does not provide sufficient glycaemic control 3 . Should dual oral treatment not be sufficient, NICE recommends to add INS on top of oral treatment 3 . .
Base case ■ Throughout the simulation, the MET + ExQW algorithm showed greater sustained weight loss ( Figure 1 ). ■ Differences in weight progression can be attributed to the weight lowering effect of MET + ExQW treatment, and the assumption that weight was maintained until the next treatment switch, supported by the long-term clinical trial 6, 7, 8 data. Treatment with MET + glargine (blue line, Figure 1 ) causes an increase in weight. 
Sensitivity analyses
■ The impact of uncertainty on results, was investigated using deterministic univariate analyses (UA) and a multivariate probabilistic sensitivity analysis (PSA). ■ Two additional scenarios were conducted to address the uncertainty of parameters or choices that could not be fully captured by the UA and PSA: ■ First scenario: Utility values, assigned to BMI change, were set to zero to observe the impact of full absence of health effects related to BMI changes. ■ Second Scenario: HbA1c switching threshold was set to 7%.
■ The tornado graphs on incremental costs and effects, resulting from the deterministic sensitivity analyses, are presented in Figure 3 .
■ Results of the PSA showed that at a threshold of £ 20,000, the probability of the MET + ExQW algorithm being cost-effective, over the MET + glargine algorithm, was 83 % ( Figure 5 ). Additionally, 100 % of the simulations resulted in ICURs being in the upper-right of the PSA scatterplot, denoting that additional QALYs can be gained at an additional cost, when the MET + ExQW algorithm was used. (Figure 4 ).
■ Treatment with the MET + ExQW algorithm resulted in 0.123 additional quality adjusted-life years (QALYs) gained, over the MET + glargine algorithm, at an additional cost of £ 1,722. The incremental QALYs are mostly explained by the difference in weight, while the higher treatment costs of ExQW drive the result on incremental costs. This resulted in a base case incremental cost-utility ratio (ICUR) of £ 13,967/ QALY gained. An overview of the (base case) results is presented below (Table 4) .
Model structure ■ The peer-reviewed and published CARDIFF diabetes modelling framework [9] [10] [11] , a lifelong stochastic simulation model, was used to assess disease progression and the cost-effectiveness. ■ Basic simulation settings were similar to previous research 12 .
■ An annual discount rate of 3.5% was applied to both costs and health effects, as suggested by NICE 13 . ■ A lifetime horizon was applied to capture the chronic nature of the disease. has been used before for assessment of other diabetic agents by health authorities.
Target population and comparators
Cost parameters
■ UK specific sources and assumptions, previously reported by Charokopou et al. 2013 12 , were used to retrieve cost inputs related to drug acquisition, diabetes-related complications, adverse events (one general practitioner visit cost), discontinuation of treatment, hypoglycaemia and renal monitoring costs (assumed to incur one general practitioner visit cost and a 24-hour urine creatinine clearance determination). An overview of the applied drug acquisition costs can be seen in Table 3 . 
ICUR (MET + ExQW algorithm vs. MET + glargine algorithm) £ 10,835/ QALY
Abbreviations: BMI, body mass index; AE, adverse events; IHD, ischemic heart disease; MI, myocardial infarction; CHF, chronic heart disease.
Discussion & Conclusions
Acknowledgements ■ Evidence presented here shows that, if the data from the follow-up clinical trial 7 is incorporated into the model, the time of insulination can be potentially extended by 4.9 years by treating patient with ExQW instead of an immediate switch to insulin (after failure of MET with or without SU). ■ The life-long treatment with the MET + ExQW algorithm results in additional QALYs gained, due to maintained weight loss, at an additional cost. ■ The predicted balance between health benefits and additional costs, denoted by an ICUR of £ 13,967/ QALY, and the uncertainty around the incremental values seems acceptable for NICE. ■ Study limitations are:
■ It is yet uncertain how weight progresses over time when patients discontinue a treatment associated with weight loss. ■ Treatment switches in the model happen when a predefined HbA1c threshold is reached. In a clinical setting, however, other factors may lead to a switch, such as worsening of adverse events, disease. These factors are not captured in our analyses. 6 . The annual cost is displayed above, however, in the model weight changed over time, hence the actual annual cost of glargine (with dosage according to weight) in the economic analysis varies according to the simulated change in weight.
‡ For the cost of intensified-glargine, it was assumed that patients received the official daily dose of 40 IU. , the weight lowering effect of MET + ExQW, was applied in the first year of treatment and was maintained until the next treatment switch based on the exenatide once weekly long-term evidence 6, 7 . For the other, subsequent treatments (i.e. MET + glargine and glargine intensified), natural weight progression was assumed after the first year of the treatment effect. 
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* Effects apply to the first year after treatment initiation. ** No estimate available and/or zero value assumed. # Probability of discontinuation was applied during the first model cycle. ∞ Probabilities of adverse events were applied during every model cycle.
For MET+glargine intensified the same efficacy data as per MET+glargine were applied. The insulin intensification was only captured in the costs as indicated in Table 3 .
